Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

The Potential Clinical Utility of Cross-Trial Comparisons: An Example From Gynecologic Cancer Literature

January 12th 2023

because of the differences between the characteristics of research subjects and individuals routinely cared for outside the confines of a clinical trial, appropriately designed examinations of “real-world” populations may provide a more relevant picture of the actual influence of a particular therapeutic intervention.

Luveltamab Tazevibulin Shows Encouraging Activity in Frα-Selected Advanced Ovarian Cancer

January 11th 2023

Treatment with the folate receptor α–directed antibody-drug conjugate luveltamab tazevibulin led to a 37.5% overall response rate in Frα-selected patients with advanced ovarian cancer, defined by a tumor proportion score above 25%.

Crane Helps Fellows Navigate a Fraught Time in Gynecology

January 10th 2023

Erin K. Crane, MD, MPH, talked to Oncology Fellows about helping trainees care for their own health and wellness, navigate the politics surrounding gynecologic care, and the lessons she hopes they take away from the program.

Discussing Dose Reductions and Interruptions with Patients on Therapy for Endometrial Cancer

January 6th 2023

Kimberly A. Spickes, CNP, discusses how often patients with endometrial cancer have dose reductions or interruptions at her institution, and who is involved in the decision to dose-reduce.

Proactive Adverse Effect Management for Patients on Therapy for Endometrial Cancer

January 6th 2023

Nurse Practitioner Kimberly Halla explains the proactive measures she takes to ensure patients with endometrial cancer are prepared to experience and manage the adverse effects of treatment.

PDS0101-Based Triplet Produces Prolonged OS in Refractory HPV+ Cancers

January 3rd 2023

Treatment with PDS0101 plus the tumor-targeting IL-12 fusion protein M9241 and bintrafusp alfa elicited encouraging overall survival data in patients with checkpoint inhibitor–naïve and –refractory advanced human papillomavirus–positive anal, cervical, head and neck, vaginal, and vulvar cancer.

Treatment Complexities Continue to Mount in Gynecologic Cancers

January 3rd 2023

Data concerning the long-term benefit of PARP inhibitors as maintenance therapy for select patients with ovarian cancer in later-line settings have come under fire in 2022 as several agents have failed to demonstrate improvements in OS outcomes.

Physicians Turn to Molecular Profiling to Drive Treatment Decisions in Endometrial Cancer

December 29th 2022

Ritu Salani, MD, MBA, discusses the continued evolution of molecular profiling in endometrial cancer, advances in immunotherapy for endometrial and cervical cancer, and ongoing research in gynecologic cancers.

Researchers Advance a Novel Screening Test for Early-Stage Ovarian and Endometrial Cancer

December 28th 2022

Peter Dottino, MD, FACOG, discusses the need for more accurate early screening tests for ovarian cancer, why testing for early-stage endometrial cancer is also important, the process used to develop the screening test, and how it could be implemented into practice if it is approved by the FDA.

Leading The Field of Rare Ovarian Cancers to New Heights

December 27th 2022

During his career, David M. Gershenson, MD, has helped turn ovarian cancer treatment into an evidence-based field and built better therapies through an improved biological understanding of the disease.

Approval of Mirvetuximab Soravtansine Provides Support for ADCs in the Ovarian Cancer Treatment Paradigm

December 26th 2022

Caroline Billingsley, MD, discusses the effect of mirvetuximab soravtansine’s approval on the treatment landscape in ovarian cancer and avenues for future research with antibody-drug conjugates and immunotherapy in this space.

Adverse Events Seen With Combination Lenvatinib and Pembrolizumab for Recurrent Endometrial Cancer

December 22nd 2022

Kimberly A. Spickes, CNP, details the adverse events she sees with combination lenvatinib and pembrolizumab treatment for recurrent endometrial cancer.

Monitoring Patients on Therapy for Recurrent Endometrial Cancer

December 22nd 2022

Kimberly Halla, NP, describes the standards for monitoring patients on therapy for recurrent endometrial cancer, including how often patients are seen in-person.

Overall Survival Is a Highly Relevant but Potentially Problematic End Point in Randomized Trials

December 21st 2022

Overall survival is a critically relevant end point in randomized oncology clinical trials, but its interpretation is often not as straightforward as some may wish to acknowledge.

Educating Patients With Endometrial Cancer on Treatment-Related Adverse Events

December 13th 2022

The panel explains how to educate patients on the adverse effects they may experience with chemotherapy, their options for management, and the importance of encouraging patients to contact their care team.

Treatment Options for Patients with Recurrent Endometrial Cancer

December 13th 2022

The panel reviews the second-line treatment options for patients with recurrent endometrial cancer.

Institutional Perspectives in Cancer: Ovarian Cancer - Chaired by Leslie R. Boyd, MD

December 12th 2022

Institutional Perspectives in Cancer: Ovarian Cancer - Chaired by Leslie R. Boyd, MD

Efficacy of Chemotherapy in Patients with Advanced Endometrial Cancer

December 7th 2022

Nurse Practitioner Kathleen Lutz talks about the efficacy of chemotherapy in patients with endometrial cancer, and how she discusses the chance of disease recurrence with patients.

Common Adverse Events Seen With Chemotherapy for Advanced Endometrial Cancer

December 7th 2022

Continuing her discussion, Kathleen highlights the most common adverse events she sees in patients treated with chemotherapy for advanced endometrial cancer who are unfit for surgery.

FDA Approvals of Immunotherapy in Gynecology Oncology

December 7th 2022

In this seventh episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, walk through a timeline of FDA approvals of immunotherapy approaches in gynecologic oncology and discuss associated toxicities to be aware of as well as how to manage them.